Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.
PENELOPE B is a phase III international, multicentre, randomised, placebo-controlled, double-blind trial comparing the efficacy and safety of adding palbociclib to standard hormone therapy vs standard ...
What is the study about? IMPORT LOW investigates whether a more targeted type of radiotherapy for people with early breast cancer can reduce side effects without reducing how well the treatment works.
There are many benefits to exercise, including reducing a person’s risk of cancer. Being physically active can also be helpful for many people during and after cancer treatment. Laura-Maria Horga ...
The Institute of Cancer Research, London, works closely with trusts, foundations and charity partners who play an important part in enabling our state-of-the-art research. We recently marked a ...
A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...
Scientists at The Institute of Cancer Research, London, have found a way to identify people with inflammatory bowel disease (IBD) who are at the highest risk of developing bowel cancer. IBD includes ...
As we enter 2026, scientists at The Institute of Cancer Research, London, share the developments expected this year that could soon change how cancer is treated – from technologies designed to deliver ...
A new immunotherapy drug has shown promise for safely treating prostate cancer, a phase I trial reports. Almost half of the patients in the trial that could be evaluated saw their tumour shrink after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results